These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30501635)

  • 1. Counteracting neuroinflammation in experimental Parkinson's disease favors recovery of function: effects of Er-NPCs administration.
    Carelli S; Giallongo T; Gombalova Z; Rey F; Gorio MCF; Mazza M; Di Giulio AM
    J Neuroinflammation; 2018 Nov; 15(1):333. PubMed ID: 30501635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Grafted Neural Precursors Integrate Into Mouse Striatum, Differentiate and Promote Recovery of Function Through Release of Erythropoietin in MPTP-Treated Mice.
    Carelli S; Giallongo T; Viaggi C; Gombalova Z; Latorre E; Mazza M; Vaglini F; Di Giulio AM; Gorio A
    ASN Neuro; 2016 Oct; 8(5):. PubMed ID: 27789613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recovery from experimental parkinsonism by intrastriatal application of erythropoietin or EPO-releasing neural precursors.
    Carelli S; Giallongo T; Viaggi C; Latorre E; Gombalova Z; Raspa A; Mazza M; Vaglini F; Di Giulio AM; Gorio A
    Neuropharmacology; 2017 Jun; 119():76-90. PubMed ID: 28373075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
    Wang S; Jing H; Yang H; Liu Z; Guo H; Chai L; Hu L
    J Ethnopharmacol; 2015 Apr; 164():247-55. PubMed ID: 25666429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
    Sconce MD; Churchill MJ; Greene RE; Meshul CK
    Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
    J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naringenin Decreases α-Synuclein Expression and Neuroinflammation in MPTP-Induced Parkinson's Disease Model in Mice.
    Mani S; Sekar S; Barathidasan R; Manivasagam T; Thenmozhi AJ; Sevanan M; Chidambaram SB; Essa MM; Guillemin GJ; Sakharkar MK
    Neurotox Res; 2018 Apr; 33(3):656-670. PubMed ID: 29427283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of NAC treatment and physical activity on neuroinflammation in subchronic Parkinsonism; is physical activity essential?
    Gil-Martínez AL; Cuenca L; Sánchez C; Estrada C; Fernández-Villalba E; Herrero MT
    J Neuroinflammation; 2018 Nov; 15(1):328. PubMed ID: 30477535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
    J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tinospora cordifolia Suppresses Neuroinflammation in Parkinsonian Mouse Model.
    Birla H; Rai SN; Singh SS; Zahra W; Rawat A; Tiwari N; Singh RK; Pathak A; Singh SP
    Neuromolecular Med; 2019 Mar; 21(1):42-53. PubMed ID: 30644041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exercise in an animal model of Parkinson's disease: Motor recovery but not restoration of the nigrostriatal pathway.
    Churchill MJ; Pflibsen L; Sconce MD; Moore C; Kim K; Meshul CK
    Neuroscience; 2017 Sep; 359():224-247. PubMed ID: 28754312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease.
    Ghosh A; Kanthasamy A; Joseph J; Anantharam V; Srivastava P; Dranka BP; Kalyanaraman B; Kanthasamy AG
    J Neuroinflammation; 2012 Oct; 9():241. PubMed ID: 23092448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the hepatic Nlrp3 protects dopaminergic neurons via attenuating systemic inflammation in a MPTP/p mouse model of Parkinson's disease.
    Qiao C; Zhang Q; Jiang Q; Zhang T; Chen M; Fan Y; Ding J; Lu M; Hu G
    J Neuroinflammation; 2018 Jul; 15(1):193. PubMed ID: 29966531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.
    Pattarini R; Smeyne RJ; Morgan JI
    Neuroscience; 2007 Mar; 145(2):654-68. PubMed ID: 17258864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined 1-Deoxynojirimycin and Ibuprofen Treatment Decreases Microglial Activation, Phagocytosis and Dopaminergic Degeneration in MPTP-Treated Mice.
    Costa T; Fernandez-Villalba E; Izura V; Lucas-Ochoa AM; Menezes-Filho NJ; Santana RC; de Oliveira MD; Araújo FM; Estrada C; Silva V; Costa SL; Herrero MT
    J Neuroimmune Pharmacol; 2021 Jun; 16(2):390-402. PubMed ID: 32564332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metalloproteinase-9 contributes to inflammatory glia activation and nigro-striatal pathway degeneration in both mouse and monkey models of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism.
    Annese V; Herrero MT; Di Pentima M; Gomez A; Lombardi L; Ros CM; De Pablos V; Fernandez-Villalba E; De Stefano ME
    Brain Struct Funct; 2015 Mar; 220(2):703-27. PubMed ID: 24558048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3θ overexpression promotes recovery in the MPTP mouse model of Parkinson's disease.
    Ding H; Underwood R; Lavalley N; Yacoubian TA
    Neuroscience; 2015 Oct; 307():73-82. PubMed ID: 26314634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation.
    Chung YC; Kim SR; Park JY; Chung ES; Park KW; Won SY; Bok E; Jin M; Park ES; Yoon SH; Ko HW; Kim YS; Jin BK
    Neuropharmacology; 2011 May; 60(6):963-74. PubMed ID: 21288472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.
    Santos DB; Colle D; Moreira EL; Hort MA; Godoi M; Le Douaron G; Braga AL; Assreuy J; Michel PP; Prediger RD; Raisman-Vozari R; Farina M
    Mol Neurobiol; 2017 Mar; 54(2):1513-1530. PubMed ID: 26852411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson's disease animal model.
    Fujita A; Yamaguchi H; Yamasaki R; Cui Y; Matsuoka Y; Yamada KI; Kira JI
    J Neuroinflammation; 2018 Aug; 15(1):227. PubMed ID: 30103794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.